Journal of Cardiac Failure最新文献

{"title":"Cardiologist-Reported Reasons for Not Titrating Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction.","authors":"Stephen J Greene, Hanna K Gaggin, Lori D Bash, Dominik Lautsch, Yan Song, Mo Zhou, James Signorovitch, Andra S Stevenson, Robert O Blaustein, Javed Butler","doi":"10.1016/j.cardfail.2025.04.010","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.04.010","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Evaluation of the Heart Failure Somatic Perception Scale using Item Response Theory.","authors":"Quin E Denfeld, Corrine Y Jurgens, Shirin O Hiatt, Nathan F Dieckmann, Mary Roberts Davis, S Albert Camacho, Christopher V Chien, Christopher S Lee","doi":"10.1016/j.cardfail.2025.04.011","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.04.011","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating Composite Endpoints: Methods and Recommendations for Trial Design and Interpretation.","authors":"Jessica R Overbey, Robert J Mentz, Cora Allen-Savietta","doi":"10.1016/j.cardfail.2025.04.008","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.04.008","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes with Femoral IABP in Heart failure and Acute Myocardial Infarction Related Cardiogenic Shock.","authors":"Arthur Reshad Garan, Arvind Bhimaraj, Rachna Kataria, Aniket Rali, E Wilson Grandin, Alvaro Delgado, Ajar Kochar, Borui Li, Manreet K Kanwar, Shashank S Sinha, Jaime Hernandez-Montfort, Jacob Abraham, Song Li, Alexandra Arias-Mendoza, Hiram Bezerra, Vanessa Blumer, I-Hui Chiang, Mary Jane Farr, Justin Fried, Ann Gage, Shelley Hall, Gavin W Hickey, Onyedika Ilonze, Maya Guglin, Wissam Khalife, Ju Kim, Scott Lundgren, Jeffrey Marbach, Joseph Mishkin, Sandeep Nathan, Mohit Pahuja, Andrew Schwartzman, Van-Khue Ton, Oleg Alec Vishnevsky, Esther Vorovich, Joyce Wald, Elric Zweck, Qiuyue Kong, Paavni Sangal, Karol D Walec, Peter Zazzali, Neil M Harwani, Kevin John, Claudius Mahr, Daniel Burkhoff, Navin K Kapur","doi":"10.1016/j.cardfail.2025.04.007","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.04.007","url":null,"abstract":"<p><strong>Background: </strong>Intra-aortic balloon pump (IABP) insertion has not been shown to improve mortality in acute myocardial infarction-related cardiogenic shock (AMI-CS) but is increasingly used in heart failure-related cardiogenic shock (HF-CS).</p><p><strong>Objective: </strong>We sought to compare IABP-related outcomes in HF-CS and AMI-CS patients.</p><p><strong>Methods: </strong>The Cardiogenic Shock Working Group registry was queried for CS patients receiving femoral IABP as the first temporary mechanical circulatory support (tMCS) device. Patients were divided into those with AMI-CS or HF-CS and were excluded if they received the IABP in conjunction with VA-ECMO or another device concomitantly. Outcomes including rates of native heart survival (NHS, i.e. weaned from IABP and discharged), heart replacement therapy (HRT, i.e. bridge to durable left ventricular assist device or heart transplant), need for another tMCS device, and death were recorded and compared between the two cohorts.</p><p><strong>Results: </strong>In total, 886 patients were supported by IABP as the first tMCS device; of these, 407 (45.6%) had HF-CS and 384 (43.3%) AMI-CS. Those with HF-CS were younger but had a higher burden of cardiovascular co-morbidities than those with AMI-CS. Among the HF-CS cohort, 33.2% had NHS and 26.7% were bridged to HRT without another tMCS device. In the AMI-CS cohort, 43.4% had NHS and 2.1% were bridged to HRT without another tMCS device. Mortality was higher in AMI-CS (36.4% vs 20.6%, p<0.001). Complication rates were higher in AMI-CS and those needing another tMCS device.</p><p><strong>Conclusion: </strong>Patients with HF-CS were more likely to have a favorable outcome with IABP than those with AMI-CS.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aggressive Up-titration of Heart Failure Guideline-Directed Medical Therapies in Cardiogenic Shock Supported by a Percutaneous Ventricular Assist Device.","authors":"Tim Balthazar, Matthias Raes, Tom Carmeliet, Ines Van Loo, Stijn Lochy, Jean-François Argacha, Danny Schoors, Bert Vandeloo, Michael Mekeirele, Joop Jonckheer, Mark La Meir, Frederik H Verbrugge","doi":"10.1016/j.cardfail.2025.04.006","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.04.006","url":null,"abstract":"<p><strong>Background: </strong>Survival after cardiogenic shock (CS) remains dismal and largely unaltered in clinical trials, contrasting heart failure with reduced ejection fraction where new drugs have established guideline directed therapy, improving long term outcomes. Unfortunately, unfavorable effects on blood pressure and glomerular perfusion limits their use in CS. A percutaneous ventricular assist device (pVAD) supports cardiac output and blood pressure, offering an option to counteract these negative drug effects.</p><p><strong>Objectives: </strong>This study aimed to evaluate if a protocol prolonging pVAD support to up-titrate heart failure drugs, is feasible and safe.</p><p><strong>Methods: </strong>All CS patients treated with pVAD after the introduction of the protocol in October 2021 were included as was a control group of patients between 2019 and October 2021. Data were retrospectively extracted from health records to calculate the use of heart failure drugs and study outcomes.</p><p><strong>Results: </strong>28 patients were in the intervention cohort, 33 in the historical cohort. Median ages were 61 and 68 years and acute myocardial infarction was predominant etiology. SCAI shock stages were D or E in 82% vs 69% (p=0.449). Lactate levels were 6.2 mmol/L (2.8-9.9 mmol/L) and 6.6 mmol/L (2-12 mmol/L); p=0.341. In the intervention group, at discharge, 94% was treated with spironolactone 25 mg, 94% with dapagliflozin/empaglifozin 10 mg, 100% with valsartan or sacubitril/valsartan and 94% with rate control, associated to significantly higher treatment intensity, compared to the historical cohort. 90-day survival was 71% in the intervention group vs 52% in the historical cohort (p=0.081), and complications rates were comparable.</p><p><strong>Conclusion: </strong>Prolonging pVAD support to uptitrate medical therapy is feasible and safe.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Building a Heart Failure Workforce for the 21st Century","authors":"G. Michael Felker MD, MHS","doi":"10.1016/j.cardfail.2025.04.003","DOIUrl":"10.1016/j.cardfail.2025.04.003","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 5","pages":"Pages 874-875"},"PeriodicalIF":6.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidney Replacement Therapies in Advanced Heart Failure: Timing, Modalities and Clinical Considerations","authors":"RAMZI IBRAHIM MD ,&nbsp;CHELSEA TAKAMATSU MD ,&nbsp;ABDULLA ALABAGI MD ,&nbsp;HOANG NHAT PHAM MD ,&nbsp;BIJIN THAJUDEEN MD ,&nbsp;SEVAG DEMIRJIAN MD ,&nbsp;W.H. WILSON TANG MD ,&nbsp;PREETHI WILLIAM MD","doi":"10.1016/j.cardfail.2024.09.014","DOIUrl":"10.1016/j.cardfail.2024.09.014","url":null,"abstract":"<div><div>Acute kidney dysfunction is commonly encountered in patients with advanced heart failure (HF), and it carries significant prognostic implications, often leading to poorer outcomes and increased mortality rates. It can alter the course of decision making for left ventricular assist device (LVAD) and cardiac transplantation candidacy. Kidney replacement therapies (KRTs) offer a critical intervention in this context but require careful consideration of timing, various types of KRT modalities and individual patients’ preferences and circumstances. This review discusses the intricacies of KRT in advanced HF, examining how to optimize timing and choose among the various KRT modalities. It also provides a detailed discussion of the unique clinical scenarios that clinicians may face when treating this vulnerable patient group.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 5","pages":"Pages 833-844"},"PeriodicalIF":6.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Let the Light In: Examining Assumptions About Racial Disparities and RAAS Inhibitors","authors":"LISA PETERS PharmD, BCPS ,&nbsp;CRAIG J. BEAVERS PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP","doi":"10.1016/j.cardfail.2025.03.009","DOIUrl":"10.1016/j.cardfail.2025.03.009","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 5","pages":"Pages 810-812"},"PeriodicalIF":6.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HFSA Membership – Join A Community of “Your People”","authors":"Mark H. Drazner MD, MSc","doi":"10.1016/j.cardfail.2025.04.004","DOIUrl":"10.1016/j.cardfail.2025.04.004","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 5","pages":"Pages 876-877"},"PeriodicalIF":6.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationale and Design of the Personalized Therapy Study: Evaluating Real-World Performance of Two Automated Defibrillation Therapy Algorithms","authors":"RAYMOND YEE MD, FRCPC ,&nbsp;CHARLES J. LOVE MD ,&nbsp;DANIEL W. KAISER MD ,&nbsp;ULRIKA BIRGERSDOTTER-GREEN MD, FHRS ,&nbsp;YONG-MEI CHA MD ,&nbsp;JAGMEET P. SINGH MD ,&nbsp;SHUFENG LIU MS ,&nbsp;YAN ZHANG MS ,&nbsp;EUGENE S. CHUNG MD","doi":"10.1016/j.cardfail.2024.11.011","DOIUrl":"10.1016/j.cardfail.2024.11.011","url":null,"abstract":"<div><h3>Background</h3><div>Barriers to maximizing patient benefit with implantable defibrillation devices include limited ability to tailor antitachycardia pacing (ATP) therapy in real time and identify patients at risk of heart failure (HF) events early on. The Personalized Therapy study aims to evaluate the performance of 2 algorithms, intrinsic ATP (iATP) and TriageHF, to address these barriers in routine clinical practice.</div></div><div><h3>Methods and Results</h3><div>The Personalized Therapy Study was designed as a prospective, multicenter, post-market registry study expected to enroll approximately 2200 patients meeting the following criteria: (1) implanted with a study-eligible device regardless of procedure type, (2) Medtronic CareLink Network enrolled, (3) TriageHF enabled within CareLink and High-Risk Alert notifications turned ON, and (4) iATP enabled. The primary study objectives are to demonstrate iATP effectiveness in the fast ventricular tachycardia zone and estimate the positive predictive value of TriageHF high-risk status for worsening HF. Additionally, objectives include characterizing iATP effectiveness in all ventricular detection zones and characterizing TriageHF-based clinical actions and related HF hospitalizations.</div></div><div><h3>Conclusion</h3><div>This study is expected to generate real-world evidence on the performance of the iATP and TriageHF algorithms, which aim to improve clinical practice by tailoring arrhythmia and HF therapies to individual patient disease states.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 5","pages":"Pages 824-832"},"PeriodicalIF":6.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}